SCHEMBL1604258

SCHEMBL1604258

Fc1ccc(-c2c(Cl)sc3ncnc(Cl)c23)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 2/20 0.56
ALDH1A1 P00352 1/20 0.56
MAPT P10636 4/20 0.41
KMT2A Q03164 2/20 0.41
HTT P42858 2/20 0.41
MRGPRX1 Q96LB2 4/20 0.41
KDR P35968 2/20 0.40
KIT P10721 1/20 0.40
TEK Q02763 1/20 0.40
MEN1 O00255 1/20 0.39
NPSR1 Q6W5P4 1/20 0.37
FGFR1 P11362 1/20 0.34
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
RAF1 P04049 1/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369189 0.85 KDR (0.55) SMN1; SMN2LMNAALDH1A1KMT2AMRGPRX1
SCHEMBL29688985 0.81 MRGPRX1 (0.62) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL16815522 0.76 SMN1; SMN2 (0.54) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL9045424 0.75 SMN1; SMN2 (0.50) SMN1; SMN2LMNAALDH1A1MAPTKIT
SCHEMBL20262700 0.73 SMN1; SMN2 (0.47) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL22320501 0.73 SMN1; SMN2 (0.44) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL1604911 0.72 SMN1; SMN2 (1.00) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL20742698 0.71 MAPT (0.43) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL18342662 0.71 SMN1; SMN2 (0.43) SMN1; SMN2LMNAALDH1A1MAPTKMT2A
SCHEMBL2368680 0.69 FGFR1 (0.55) SMN1; SMN2ALDH1A1MAPTKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2011-04-07 US disclosed
EP-1797099-B1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE INC (US) 2010-08-11 EP disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds TROVIS PHARMACEUTICALS, LLC 2010-05-06 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
US-7612078-B2 Piperidinylamino-thieno[2,3-D] pyrimidine compounds EPIX DELAWARE, INC. (US) 2009-11-03 US disclosed
EP-1797099-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS Epix Delaware, Inc. (US) 2007-06-20 EP disclosed
WO-2006034511-A1 PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS EPIX DELAWARE, INC. (US) 2006-03-30 WO disclosed
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds TROVIS PHARMACEUTICALS, LLC 2005-10-06 US disclosed
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds PGXHEALTH, LLC 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222175-A1 New piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR5A, HTR3A, HTR1A SMN1; SMN2 1416/4885LMNA 2240/4885ALDH1A1 1234/4885
US-20100113485-A1 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds HTR2B, HTR3B, HTR1B SMN1; SMN2 4727/4885LMNA 3979/4885ALDH1A1 1583/4885
US-20050222176-A1 Piperidinylamino-thieno[2,3-D] pyrimidine compounds HTR2B, HTR3B, HTR1B SMN1; SMN2 4727/4885LMNA 3979/4885ALDH1A1 1583/4885
US-20110082157-A1 Piperidinylamino-Thieno [2,3-D] Pyrimidine Compounds HTR5A, HTR3A, HTR1A SMN1; SMN2 1383/4885LMNA 2460/4885ALDH1A1 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.